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Background: Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme
α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues. We report
on the safety and pharmacodynamics of migalastat hydrochloride, an investigational pharmacological chaperone
given orally at 150 mg every-other-day.
Methods: Two open-label uncontrolled phase 2 studies of 12 and 24 weeks (NCT00283959 and NCT00283933) in
9 males with FD were combined. At multiple time points, α-Gal A activity and GL-3 levels were quantified in blood
cells, kidney and skin. GL-3 levels were also evaluated through skin and renal histology.
Results: Compared to baseline, increased α-Gal A activity of at least 50% was demonstrated in blood, skin and
kidney in 6 of 9 patients. Patients’ increased α-Gal A activities paralleled the α-Gal A increases observed in vitro in
HEK-293 cells transfected with the corresponding mutant form of the enzyme. The same 6 patients who
demonstrated increases of α-Gal A activity also had GL-3 reduction in skin, urine and/or kidney, and had α-Gal A
mutations that responded in transfected cells incubated with the drug. The 3 patients who did not show a
consistent response in vivo had α-Gal A mutations that did not respond to migalastat HCl in transfected cells.
Migalastat HCl was well tolerated.
Conclusions: Migalastat HCl is a candidate pharmacological chaperone that provides a novel genotype-specific
treatment for FD. It enhanced α-Gal A activity and resulted in GL-3 substrate decrease in patients with responsive
GLA mutations. Phase 3 studies are ongoing.
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Fabry disease (FD, OMIM 301500) is a rare, X-linked,
multi-system genetic disorder [1]. Absent or deficient
activity of lysosomal exoglycohydrolase α-galactosidase
A (α-D-galactoside galactohydrolase, EC 3.2.1.22; α-Gal
A) results in progressive accumulation of globotriaosyl-
ceramide (Gb3 or GL-3) and related glycosphingolipids
within lysosomes in a variety of cell types, including ca-
pillary endothelial cells, and renal (podocytes, tubular
cells, glomerular endothelial, mesangial and intersticial
cells), and nerve cells [1]. The primary disease process
starts in infancy. With age, progressive damage to vital
organ systems develops leading to organ failure. End-
stage renal disease and life-threatening cardiovascular or
cerebrovascular complications limit life-expectancy [1].
Treatment with life-long enzyme replacement therapy
(ERT) infusions is available [2,3]. However, due to con-
cerns regarding convenience, cost and incomplete effects
on disease progression, unmet medical needs remain
and other treatments are under investigation [1,4].
Studies of α-Gal A indicate that mutant forms of the
enzyme are often retained in the endoplasmic reticulum
(ER) and prematurely degraded because of reduced sta-
bility or improperly folded conformations [5,6] as in
other conformational or protein-misfolding diseases.
This provides a rationale to use active site-specific
pharmacological chaperones that bind and stabilize the
nascent protein and restore efficient enzyme trafficking
to lysosomes, the site of α-Gal A activity [5,7]. Migalastat
HCl (AT-1001, GR181413A, 1-deoxygalactonojirimycin)
is a low molecular weight iminosugar that is orally bio-
available and that acts as a pharmacological chaperone
for α-Gal A, targetting α-Gal A mutants that maintain
catalytic competence [5,8]. The mechanism of action of
migalastat HCl is to bind and stabilize mutant α-Gal A
initially in the ER, preventing misfolding and premature
degradation and facilitating cellular trafficking to lyso-
somes where the breakdown of the GL-3 substrate can
proceed [8,9].
We report on two phase 2 studies exploring the safety
and pharmacodynamic responses to migalastat HCl in
male patients with FD. In both studies, multiple para-
meters were evaluated to assess the effect of migalastat
HCl on mutant α-Gal A activity and tissue GL-3.
Patients and methods
Two open-label, uncontrolled, phase 2 studies (FAB-CL-
202, NCT00283959 and FAB-CL-203, NCT00283933,
respectively) were conducted to evaluate the safety, tol-
erability, and pharmacodynamics of migalastat HCl in
males with FD. Alpha-galactosidase A activity and GL-3
levels were evaluated in blood, urine, skin and kidney.
Patients were treated with migalastat HCl 150 mg orally
every other day for 12 weeks (FAB-CL-202) or 24 weeks(FAB-CL-203). Both studies incorporated a treatment
extension for a total duration of 48 weeks. The studies
received Ethical Committee/Institutional Review Board
(IRB) approval and were conducted according to
accepted standards of Good Clinical Practice (ICH-GCP)
and in agreement with the Declaration of Helsinki.
Safety and pharmacodynamic data are presented for
the first 12 to 24 weeks of initial treatment and, when
available, include data from week-48 renal biopsies.
Patients
Inclusion and exclusion criteria were similar for both
studies. After written informed consent, male patients
between 18 and 65 years of age with a confirmed diag-
nosis of FD were enrolled (Table 1). A missense muta-
tion in the GLA gene and residual α-Gal A activity of at
least 3% of normal were required, as was the demonstra-
tion of an increase in α-Gal A activity in the presence of
migalastat HCl in patient cultured lymphocytes. The ini-
tial criteria for enhancement required a relative increase
in α-Gal A activity of at least 20% in the presence of
20 μM migalastat HCl. These criteria were later
amended to a graded scale: if baseline activity was less
than 1% of normal, it had to increase to at least 2% of
normal; if activity was between 1% and 3% of normal, it
had to at least double; if baseline activity was between
3% and 10%, it had to increase by at least 3% of normal;
and if baseline activity was above 10%, it had to increase
by at least 30%. Patients were to be naïve to ERT or will-
ing to stop ERT for the duration of the study. Main ex-
clusion criteria were significant disease or organ
dysfunction, serum creatinine above 2 mg/dL and a QTc
interval longer than 450 ms.
The schedule of evaluation for α-Gal A activity and
GL-3 parameters is shown in Table 2. Skin biopsies and
kidney biopsies were obtained at multiple time points.
Measurement of α-Gal A activity
At screening, patient lymphocytes were isolated from
blood and cultured in media containing interleukin-2
and phytohemagglutin. Lymphocyte α-Gal A activity was
measured in cell lysates with a fluorimetric assay using
4-methylumbelliferyl α-D-galactopyranoside as a sub-
strate in the presence of galactosamine. Alpha-Gal A ac-
tivities were measured alone and after 3 days of in vitro
incubation with 20 μM migalastat HCl [10]. Fulfillment
of the enhancement criteria was reported as Yes/No.
At screening and multiple time points during studies,
peripheral blood mononuclear cells (PBMCs) were iso-
lated and α-Gal A activity was measured using the previ-
ously described method [10] (MDS Pharmaceutical
Services, Lincoln, NE). Values were normalized to mea-
sured total protein using a colorimetric assay and α-Gal
A activity was reported as nmol/hour/mg protein.
Table 1 Baseline characteristics
Patient
ID
Age
(years)
eGFR (mL/min/
1.73 m2)
24-hour protein
(mg)
Left Ventricle Mass
(g)
GLA
mutation
HEK assay: amenable
mutation?
2-0102 27 143.8 270 138 p.L415P NO
2-0103 23 127.3 147 228 p.P259R YES
2-0104 18 156.1 131 123 p.P259R YES
2-0202 65 33 4640 312 p.R301Q YES
3-0301 39 121.1 –a 225 p.F295C YES b
3-0302 31 134.5 –a 144 p.C94S NO
3-0303 36 90.3 –a 175 p.R112C NO
3-RF01 55 92.5 <100 231 p.N215S YES
3-RFO3 47 135.7 150 200 p.P205T YES
a Value not available.
b Mutation was amenable only when higher doses of migalastat hydrochloride were used.
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centage of normal. The normal value was determined to
be 22.0 +/− 5.7 nmol/hr/mg protein (mean +/− SD mea-
sured in 16 healthy volunteers in the migalastat HCl
phase 1 study FAB-CL-102).
At baseline and during treatment skin and kidney bi-
opsies were analyzed for α-Gal A activity in aqueous
homogenates using a non-GLP method derived from theTable 2 Schedule of evaluations for α-Gal A activity (lymphoc
kidney) and GL-3 (plasma, 24-hour urine, skin and kidney)
Screening Baseline W4
α-Gal A activity
Lymphocytes +
PBMCs + + +
Skin +
Kidney +
GL-3
Plasma + + +
Urine + + +
Skin
LC/MS +
LM, EMa +
LM Semi Qb +
LM Quantitativec +
Kidney
LC/MS +
LM, EMa +
LM Semi Qb +
LM Quantitativec +
W=week, α-Gal A = alpha-galactosidase A, PBMCs = Peripheral Blood Mononuclear
globotriaosylceramide, LM = Light Microscopy, EM = Electron Microscopy, Q = Quant
a Multiple cell types using a subjective scoring scale of 0, 1, 2, or 3 based on increa
b Peritubular capillaries using a modified Thurberg’s method 14.
c Peritubular capillaries quantifying the number of GL-3 inclusion per cell using the
d FAB CL-202 (NCT00283959) only.
e FAB CL-203 (NCT00283933) only.PBMC method (MDS, Montreal, Canada). Timing of
samples is reported in Table 2. Aqueous homogenization
protocols for skin and kidney were developed and opti-
mized for recovery of α-Gal A activity. Because enzyme
activities may vary between tissues and even between
cells within the same tissue, modifications were made to
address technical issues associated with the limited
amount of material and the potential for measuredytes, peripheral blood mononuclear cells, skin and
W8 W12 W16 W20 W24
+ + +e +e +e
+ +e
+d +e
+ + +e +e +e
+ + +e +e +e
+ +e
+ +e
+ +e
+ +e
+d +e
+d +e
+d +e
+d +e
Cells, LC/MS = Liquid Chromatography/Mass Spectrometry, GL-3 =
itative.
sing GL-3 content.
the BLISS method 15.
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treatment samples. Protocol modifications took into
consideration the possibility for measured values to be
above the level of detection but with insufficient sample
volume to re-assay with dilution. The assay showed ac-
tivity values varying by less than 10% in the kidney and
by less than 20% in the skin. Control samples demon-
strated good linearity over 50 serial 2-fold dilutions
(average of <10% difference between predicted and mea-
sured signal). Measured values after 10-fold dilutions of
the tissue samples were on average within 15% of pre-
dicted values for kidney, and within 25% of predicted
values for skin.
Measurement of α-Gal A activity in HEK-293 cells
In parallel with these studies, efforts to better define the
range of α-Gal A mutant forms that are amenable to
migalastat HCl were implemented. An in vitro α-Gal A
gene transfection assay, specific for each individual mu-
tation, was developed in HEK-293 cells [11]. Criteria for
response in the presence of 10 μM migalastat HCl were
both an absolute increase of 3% of normal activity and a
20% relative increase [11]. The HEK-293 assay was retro-
spectively used to define if a patient carrying a GLA mu-
tation was amenable to migalastat HCl.
Measurement of GL-3
Plasma GL-3
Plasma GL-3 levels were measured at MDS Pharma
(Lincoln, NE). An aliquot of human plasma (with EDTA)
containing the analyte and internal standard was
extracted using a precipitation procedure under UV-
shielded conditions. The extracted samples were ana-
lyzed by high performance liquid chromatography
(HPLC) coupled with an AB/MDS Sciex API 4000 mass
spectrometer (MS). Using a closely related assay in 205
healthy volunteers, the mean (SD) normal value was
estimated to be 3.5 (1.3) μg/mL [12].
Urine GL-3 (u-GL-3)
Whole urine GL-3 measurements on 24-hour samples
were performed using LC-MS/MS analysis. Initially, de-
termination was done at MDS Pharma Services (lower
limit of detection 1 μg/mL). As most samples had levels
of GL-3 that were below this limit of quantification, a
more sensitive analysis was used. Samples were analyzed
at the Department of Genetic Medicine, Women’s and
Children’s Hospital, North Adelaide, Australia. Urine
sediment was subjected to sonication to fragment cells.
Urinary lipids from sediment and supernatant were
extracted by liquid-liquid extraction. Following chroma-
tography, GL-3 isoforms were detected by electrospray
ionization tandem mass spectrometry in multi-reaction
mode. Total GL-3 was reported as the sum of fiveisoforms (C16:0, C20:0, C22:0, C24:0, C24:1). The lower
limit of detection was approximately 1 ng/mL. To cor-
rect for urinary sediment cell content, GL-3 was normal-
ized to total phosphatidylcholine (PC) determined in the
same LC-MS/MS assay. Results were expressed in pmol
GL-3/nmol PC [13]. Urine GL-3 was also measured in
samples from healthy volunteers. The mean (SD) urine
GL-3 value in 29 healthy male volunteers was 48.6 (13.0)
pmol GL-3/nmol PC. Subject values above 74.6 pmol
total GL-3/nmol PC (mean + 2 SDs) were considered
abnormal.
Skin and kidney GL-3
GL-3 was measured in skin and kidney tissues with LC-
MS/MS under non-GLP conditions on aqueous samples
derived from tissue homogenates (MDS Pharma Ser-
vices, Montreal, Canada). The homogenization protocol
was the same as for α-Gal A activity. After chromatog-
raphy, GL-3 isoforms were detected using electrospray
ionization tandem mass spectrometry in multi-reaction
mode. The amount of GL-3 in the sample was reported
as the sum of nine isoforms. Results were expressed as
micrograms GL-3/g of tissue. The analytical range of the
assay was 0.1 to 5.0 μg/g of tissue.
Skin and kidney histology
GL-3 accumulation was measured by histology in skin
and kidney biopsies in multiple cell types. Analysis was
performed using both light microscopy (LM) on
glutaraldehyde-fixed and plastic-embedded sections
stained with methylene blue-Azure II, and by electron
microscopy (EM). Pathologists were blinded to the tim-
ing of the sample.
In skin and kidney, a GL-3 score was assigned by a
single pathologist based on a semi-quantitative scale,
with zero representing no GL-3 and three representing
the most severe GL-3 accumulation [14]. In kidney, cells
included podocytes, distal tubular cells and peri-tubular
capillary endothelial cells (PTCs) [14]. For PTCs, the cell
type previously used to determine the primary measure
of efficacy for registration studies [14], the sensitivity of
GL-3 analysis was further improved by using a novel
scoring system, the Barisoni Lipid Inclusion Scoring Sys-
tem (BLISS) [15]. Two pathologists independently
counted the total number of GL-3 inclusions per capil-
lary in all 50–180 recorded capillaries and summarized
the average score per PTC. The final BLISS score was
the average of both pathologists’ scores.
Distal kidney tubules were also qualitatively evaluated
for GL-3. Two pathologists individually determined
whether there were fewer, equal, or more GL-3 inclu-
sions present at the available time points.
A qualitative analysis of glomerular sclerosis was per-
formed. For each available time point, two pathologists
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that were normal or sclerotic and further sub-categorized
them as globally or segmentally sclerotic.
Finally, pharmacodynamic responses for α-Gal A activ-
ity and GL-3 were summarized for each patient to deter-
mine an overall individual response (post-hoc analysis).
A positive response for α-Gal A activity was defined as
an increase of at least 50% above baseline. Changes in
GL-3 parameters were assessed as a percentage decrease
from baseline of ≥ 20% for u-GL-3 and ≥50% in GL-3 in-
clusion number in PTCs. Evidence of an overall response
was considered to be present if enhancement of α-Gal A
activity was associated with GL-3 reduction in skin and/
or kidney.
Safety
Adverse events (AE), serious adverse events (SAE), la-
boratory (hematology, chemistry, and urinalysis) and pa-
tient drops-outs were evaluated all along the studies and
extension periods.
When appropriate, descriptive statistics (mean, SD)
were provided. Because of the small number of patients
and the uncontrolled nature of the studies, no inferential
statistics were used. Results are presented as individual
patient data.
Results
Studies FAB CL-202 and FAB CL-203 recruited four and
five subjects, respectively. The mean (SD) age at screen-
ing was 38 (15.4) years. The most frequent clinical mani-
festations at baseline were cold/heat intolerance (9/9),
reduced sweating (9/9), angiokeratomas (8/9), acropar-
esthesias (7/9), hypoaccousia (5/9) and proteinuria (4/9).
Three patients had hypertrophic cardiomyopathy. One
patient had renal insufficiency (eGFR 33 mL/min/
1.73 m2) (Table 1).
All patients carried a missense mutant α-Gal A that
was considered to be responsive in the initial lympho-
cyte assay. When subsequently tested in the HEK-293
transfection assay, only six patients had mutations con-
sidered amenable to migalastat HCl (p.P205T, p.N215S,
p.P259R two patients, p.F295C, p.R301Q) while three
had mutations that did not show a sufficient enzymatic
activity increase in HEK-293 cells incubated with the
drug (p.C94S, p.R112C, p.L415P) (Table 1).
Safety
Migalastat HCl was well tolerated. No subject discontin-
ued treatment for an adverse event and there was no
drop out for safety reasons. There were no deaths and
no specific AE, serious adverse event (SAE), or labora-
tory abnormalities that were deemed related to migala-
stat HCl.α-Gal A activity
At baseline, PBMC α-Gal A activity ranged from 0.05 to
6.11 nmol/hour/mg protein (Table 3). The greatest activ-
ity corresponded to 16% of normal and in 8/9 subjects
the activity was ≤ 1% of normal. During treatment,
PBMC α-Gal A activity generally increased by the first
time point and plateaued thereafter (Figure 1). For two
subjects the maximum activity was seen at the last time
point.
In skin homogenates, baseline α-Gal A activity ranged
from 0.2 to 37.3 nmol/hour/mg protein. Following treat-
ment, increases in α-Gal A activity of at least 50% were
noted for all subjects (Table 4).
In kidney homogenates, α-Gal A activity at baseline
ranged from 0.4 to 21.6 nmol/hour/mg protein. Follow-
ing treatment, increases in α-Gal A activity of at least
50% were noted for 6/9 patients (Table 4).
Plasma GL-3
At baseline, plasma GL-3 was between 1.12 and
4.82 μg/mL. No patient had values above normal. Week 12
data were not available for study FAB CL-202. One patient
showed a transient increase of plasma GL-3, but otherwise
there were no notable changes (data not shown).
Urine GL-3
All nine patients had elevated u-GL-3 prior to treatment;
with a range from 170 to 3,876 pmol total GL-3/nmol
PC. Compared to baseline, at the last time point
decreased u-GL-3 levels of at least 20% were seen in 5/9
patients (Figure 2), all of whom had HEK-293 responsive
mutations. Of the four patients without such a decrease,
three had HEK-293 non-responsive mutations.
Tissue GL-3 content
GL-3 in baseline renal biopsies ranged from 623 μg/g to
9,770 μg/g. During treatment GL-3 content decreased in
five patients (4 of whom had HEK-293 responsive muta-
tions) while 4 had an increase (Table 5). Of these four,
two had HEK-293 responsive mutations.
For skin, the baseline GL-3 content ranged from
6.7 μg/g to 360 μg/g. During treatment GL-3 content
decreased in 3 patients, all of whom had HEK-293 re-
sponsive mutations (Table 5).
GL-3 kidney histology
As LM and EM results were generally consistent, only
LM results are presented.
On the semi-quantitative LM scale, podocytes had
consistently more GL-3 than any of the other 12 renal
cell types evaluated. Even when other cells had minimal
or no inclusions (i.e., score of 0), podocytes always con-
tained GL-3 inclusions. At baseline 9/9 patients had a
podocyte score of 3 (maximum). The second most
Table 3 α-Gal A activity in peripheral blood mononuclear cells (PBMCs, nmol/hr/mg protein)
Screening Baseline Week 4 Week 8 Week 12 Week 16 Week 20 Week 24
FAB CL-202 (NCT00283959) 1
2-01022 0.15 0.14 0.14 0.18 0.12 - - -
2-0103 0.22 0.24 2.23 1.76 2.3 - - -
2-0104 0.5 0.21 2.88 3.18 3.36 - - -
2-0202 0.5 0.3 7.53 6.45 7.12 - - -
FAB CL-203 (NCT00283933) 1
3-03012 0.13 0.08 0.17 0.17 0.22 0.19 0.25 0.36
3-0302 0.18 0.10 0.08 0.07 BLQ 0.06 0.08 0.13
3-0303 BLQ 0.14 0.36 0.37 BLQ 0.22 0.42 0.3
3-RF01 6.11 2.6 8.46 12.1 10.6 11.5 8.35 10.9
3-RF03 0.04 0.2 0.3 0.57 0.38 0.51 0.34 1.32
1 Study number.
2 Patient ID.
BLQ = Below limit of quantification. Enzyme activity was reported as nmol/hour/mg protein.
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these cells were not always present on slides, making
evaluation problematic. At baseline, 2/2 patients’ collect-
ing duct cells had a GL-3 inclusion score of 3.
For PTCs, the semi-quantitative and quantitative
(BLISS) results were generally similar both at baseline
and during treatment (data not shown). The quantitative
method however was more sensitive as it could score
inclusions even if the semi-quantitative score was “0”.
The quantitative results are presented in Table 6. For 8/9
patients with available data, the baseline average count of
GL-3 inclusions per cell ranged from 0.3 to 5.9. Between
the first and last available biopsy the number of inclu-
sions decreased in 4/8 patients, remained unchanged in
2/8, and increased in 2/8. Four of six patients who hadFigure 1 PBMC α-Gal A activity (as a percentage of normal) by week
mutations amenable to migalastat HCl as measured in the HEK-293 cell-ba
mutations. Values below 0.2 are below the limit of quantification (BLQ).HEK-293 responsive mutations had a score decrease, one
had a score that did not change and one had a missing
sample at baseline. Both patients who had an increase in
score had mutations that were non-responsive in the
HEK-293 assay. Of note, the inclusion count in PTCs did
not always correlate with the changes in GL-3 on homo-
genized tissues.
Due to the variations in the number of glomeruli be-
tween biopsies, the assessment of glomerular sclerosis
change was challenging (data not shown). At baseline,
glomerulosclerosis was absent in 8/9 patients and absent
during the study. For the remaining patient (2–02) only
2 non-sclerotic glomeruli were available at baseline. For
this patient, glomerulosclerosis was noted at week 12
but was less marked at week 48.of migalastat HCl treatment. The red lines are for patients with
sed assay. The blue lines are for patients with non-responsive
Table 4 α-Gal A activity in skin and kidney (nmol 4-MU/hr/mg protein)
Skin Kidney
Baseline Week 12 Week 24 Baseline Week 12 Week 24
FAB CL-202 (NCT00283959) 1
2-0102 2 0.25 0.99 - 0.6 0.7 -
2-0103 2 0.65 34.05 - 0.8 4.7 -
2-0104 2 1.76 28.24 - 0.9 10.2 -
2-0202 2 6.97 105 - 4.4 29.9 -
FAB CL-203 (NCT00283933) 1
3-0301 2 0.92 3.08 2.6 0.4 - 1.2
3-0302 2 0.37 2.36 1.13 1.7 - 1.3
3-0303 2 0.82 2.97 1.37 0.8 - 1.0
3-RF01 2 37.29 139 133 21.6 - 157
3-RF03 2 1.22 22.77 41.88 1.5 - 14.7
1 Study number.
2 Patient ID.
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Only LM results are presented. Most patients had low
scores (0 or 1) at baseline and GL-3 inclusions were
mostly seen in capillaries (endothelial cells and peri-
cytes), large vessels (endothelial cells and medial smooth
muscle cells) or perineurium (data not shown).There
was no correlation between the presence of angiokera-
toma and GL-3 scores: two patients who had no GL-3
deposition had angiokeratomas. No skin cells were indi-
vidually as severely and consistently affected as kidney
podocytes and there was a large variability of cell scores
between patients. At baseline, the only cells that had a
score of 3 were the perineurium (4/7) and large vessel
smooth muscle cells (2/7). Results were highly variableFigure 2 Total urine GL-3 (in pmol/nmol phosphotidlycholine) by wee
AT1001-amenable mutation in the HEK-293 cell-based assay, and the blue
patient 3–0301) was responsive only when high concentrations of migalastthroughout the study (data not shown). For capillary
endothelial cells, when comparison between baseline
and week 12 and week 24 data was made, 2/9 had a de-
crease (both had mutations that were responsive in the
HEK-293 assay), 3/9 an increase, 4/9 unchanged. The
observed changes were all less than 1 scoring unit.
Composite outcome
Table 7 provides a summary of α-Gal A and GL-3
responses to migalastat HCl. Six out of nine patients had
responses in both α-Gal A and GL-3 parameters in skin
and/or kidney, and all six had α-Gal A mutations that
were responsive in the HEK-293 assay. Both patients
with the same mutation (p.P259R) had consistentk of migalastat HCl treatment. The red lines are for patients with an
lines are for those with non-amenable mutations (Mutation p.F295C in
at HCl where used). Y axis: logarithmic scale.
Table 5 Skin and kidney GL-3 content at baseline, week
12 and week 24 (μg/g tissue)
Baseline Week 12 Week 24
Skin Kidney Skin Kidney Skin Kidney
FAB CL-202 1
2-0102 2 267 4170 269 3260 - -
2-0103 337 9510 233 5590 - -
2-0104 360 9770 309 9210 - -
2-0202 10.3 4140 11.2 3250 - -
FAB CL-203 1
3-03012 223 3500 189 - 241 4960
3-0302 230 2100 259 - 349 2860
3-0303 246 623 344 - 300 2850
3-RF01 6.71 1340 9.38 - 10.3 4060
3-RF03 96.1 5300 64.8 - 41.5 3390
1 Study number.
2 Subject number.
Table 6 Quantitative GL3 scoring in kidney peri-tubular
capillaries (PTC)
Visit Reader 1 Reader 2 Average
FAB CL-2021
2-01022 Baseline 2.3 2.3 2.3
Week 12 5.7 6.6 6.2
2-0103 Baseline 4.4 7.4 5.9
Week 12 0.3 0.3 0.3
2-0104 Baseline 2.3 3.5 2.9
Week 48 0.9 1.4 1.2
2-0202 Baseline 0.5 0.2 0.3
Week 12 0.8 0.3 0.5
Week 48 0.3 0.3 0.3
FAB CL-2031
3-03012 Baseline 0.7 2.0 1.4
Week 24 3.5 - 3.5
Week 48 0 - 0
3-0302 Baseline 2.4 2.6 2.6
Week 24 3.5 5.4 4.5
Week 48 4.4 4.2 4.3
3-0303 Baseline 3.5 2.2 2.9
Week 24 1.0 1.2 1.1
Week 48 2.6 3 2.8
3-RF013 Baseline 0.4 0.1 0.3
Week 24 0.1 0.0 0.1
Week 48 - - -
3-RF034 Baseline - - -
Week 24 0.0 0.1 0.1
Week 48 0.0 0.0 0.1
Average number of GL-3 inclusions per cell as measured in biopsy samples at
different time points (BLISS).
1 Study number.
2 Subject number.
3 Week 48 biopsy not evaluable.
4 Baseline biopsy not evaluable.
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onstrate a clinical response had mutations that were not
responsive in the HEK-293 assay.
Discussion
Mutations in proteins that reduce stability or lead to
protein misfolding are common causes of lysosomal
storage diseases. Unstable or misfolded mutant enzymes
are recognized by the cellular endoplasmic reticulum
(ER) quality control system and prematurely degraded
before reaching lysosomes. Some iminosugars have a
high affinity for the active site of lysosomal enzymes,
and can reversibly bind, stabilize and act as specific
pharmacological chaperones [1,5,16,17]. Stabilized mu-
tant can pass ER quality control more efficiently and
traffic to lysosomes [7]. Once in lysosomes, the non-
covalently bound chaperones can dissociate, freeing the
enzyme to bind its substrate [5].
In FD, this approach was first demonstrated in
patients’ lymphoblasts using 1-deoxygalactonojirimycin
(migalastat HCl) [5]. Migalastat HCl mimics the terminal
α-galactose of GL-3 and binds to the active site of α-Gal
A with high affinity and specificity [6]. The binding
increases the stability of the enzyme, shifts the folding in
favor of the proper conformation and allows traffic to
lysosomes [17].
The objectives of the current studies were to explore
the safety and pharmacodynamics of migalastat HCl in 9
male FD patients given 150 mg orally every other day.
Results from a 12-week and a 24-week study with
similar design were combined. There was a consistent
increase in α-Gal A activity in PBMCs, skin and kidney
in patients carrying responsive GLA mutations. In
PBMCs, increases were rapid (week 4) and sustainedover the duration of treatment. One patient, with a low
baseline α-Gal A activity, showed a progressive increase
with a maximum only reached at week 24. Some
patients reached an enzyme activity in PBMCs of 30% to
50% of normal. Increase in α-Gal A activity were asso-
ciated with substrate reduction, as demonstrated by a
decrease in urinary GL-3 and GL-3 inclusions in renal
PTCs.
These results indicate that the activity of mutated α-
Gal A can be increased in vivo following administration
of migalastat HCl. The binding of the drug to α-Gal A is
reversible and is of lower affinity in the acidic environ-
ment of the lysosome. Furthermore, migalastat HCl is
rapidly cleared from plasma (half-life 3–4 hours),
whereas the lysosomal half-life of the enzyme is
Table 7 Summary of α-Gal A increase and GL-3 reduction for each patient and combined score according to HEK-293
response status
Patient 2-0103 2-0104 2-0202 3-0301 3RF01 3RF03 2-0102 3-0302 3-0303
Mutation p.P259R p.P259R p.R301Q p.F295C p.N215S p.P205T p.L415P p.C94S p.R112C
HEK-293 R R R R R R NR NR NR
α-Gal A PBMC (at least +50%) + + + + + + - - +
α-Gal A kidney (at least +50%) + + + + + + - - -
α-Gal A skin (at least +50%) + + + + + + + + +
u-GL3 + (−60%) + (−75%) + (−38%) - + (−20%) + (−52%) - - -
GL-3 skin LC/MS + (−31%) + (−11%) - - - + (−57%) - - -
GL-3 kidney LC/MS + (−41%) + (−6%) + (−21%) - - + (−36%) + (−22%) - -
GL-3 kidney Inclusion (−50%) + + - + + a - - -
Combined score + + + + + + - - -
HEK-293 = transfection assay in Human Embryonic Kidney-293 cells, R = responsive mutation, NR = non-responsive mutation, α-Gal A = alpha galactosidase A,
PBMCs = Peripheral Blood Mononuclear Cells, GL-3 = globotriaosylceramide, u = urine, s = skin, k = kidney, LC/MS = Liquid Chromatography - Mass Spectrometry.
a baseline biopsy not evaluable.
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allows the enzyme to bind and turn over the GL-3 sub-
strate without inhibition by the small molecule. The
every-other-day regimen allows additional time for the
chaperone to dissociate from the enzyme.
The in vitro HEK-293 cell-based assay [11] appears to
predict the clinical pharmacodynamic response. Of note,
both patients with the same p.P259R mutation showed
similar pharmacodynamic response. As these studies
included only 9 patients carrying 8 different missense
mutations, results should be interpreted with caution.
The predictive value of the assay will have to be con-
firmed in larger numbers of FD patients with additional
mutations. This assay is currently used to select patients
for phase 3 clinical studies.
FD is a rare, lifelong devastating disease, punctuated
by acute complications that take many clinical forms [1].
FD phenotypic expression varies from one patient to the
next, even within families harboring the same genotype.
It is thus a challenge to select clinical outcome measures
that can consistently demonstrate therapeutic efficacy
[18]. Because GL-3 is the primary lysosomal substrate of
α-Gal A, the deficient enzyme in FD, demonstrating a
decrease in GL-3 could reflect treatment efficacy.
While GL-3 deposition in renal PTCs has been used as
the primary outcome measure of efficacy for the ap-
proval of agalsidase beta [2], this choice may not be ap-
propriate. Despite an overt clinical expression of the
disease, our patients had limited amounts of GL-3 in ca-
pillary cells of the kidney and skin, and normal levels of
GL-3 in plasma. Kidney histology revealed that GL-3 de-
position was extensive in podocytes and collecting duct
cells, but minimal in PTCs. A previously used histo-
logical method for quantifying GL-3 in PTCs [14] wasnot sensitive enough to evaluate the low levels of inclu-
sions observed. Thus, a more sensitive method to quantify
GL-3 PTC inclusions was developed [15]. Interestingly,
the shedding into the urinary tract of tubular cells, and
potentially podocytes, accounts for most of the urinary
GL-3 in FD [19], especially when plasma GL-3 levels are
low and glomerular filtration of GL-3 negligible. A de-
crease in u-GL-3 was observed in our subjects and has
been advocated as a marker of efficacy in FD, however the
clinical relevance remains controversial [13,20]. Some of
the controversies stem from a lack of a reliable method
for collection of samples and analysis [13,21]. To address
these concerns, a new GLP assay for urine GL-3 was
developed and validated, and will be used in ongoing
migalastat HCl phase 3 studies.
In contrast to ERT, migalastat HCl is a small molecule
that is excreted unchanged in the urine and can poten-
tially reach podocytes. These cells are central to the
renal pathophysiology of FD [22]. Migalastat HCl was
generally well tolerated. However, these studies only en-
rolled 9 subjects and this should be interpreted with evi-
dent caution. Long-term extension data from phase 2
studies also indicate that the drug is well tolerated and,
as of this writing, no severe adverse reactions related to
treatment have been identified after four years of
treatment.
A key issue for physicians treating FD patients is the
selection of candidates for pharmacological chaperone
therapy. Severe GLA defects that result in no residual α-
Gal A activity are probably not addressable with
chaperone therapy, and only patients who express mis-
sense mutants with low levels of activity were included.
Different methods were explored to predict which
patients would respond to migalastat HCl [8,11]. We
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had at least 3% of normal activity that increased by at
least 20% when lymphocytes were incubated with miga-
lastat HCl. However, the ex vivo lymphocyte assay is
complex and cannot be readily performed under GLP
conditions. Moreover, the lymphocyte assay did not al-
ways correlate with the in vivo PBMC assay. Ultimately,
lymphocyte and PBMC assays are not useful in heterozy-
gous FD females. In an X-linked disease, females are
mosaics and isolated cells are a mix of cells with normal
α-Gal A and ones with mutated α-Gal A. In females, an
increase in activity with migalastat HCl might reflect the
chaperoning of the wild-type enzyme. It has been in-
creasingly recognized that females with FD can have sig-
nificant clinical manifestations [23,24]. For these
reasons, an in vitro assay was developed that could be
used irrespective of sex [11].
In summary, migalastat HCl is a candidate pharmaco-
logical chaperone that provides a genotype-specific treat-
ment for FD. When administered at an oral dose of
150 mg on an every-other-day regimen, it was well toler-
ated, increased α-Gal A activity in patients with respon-
sive GLA mutations, and resulted in GL-3 substrate
reduction. Phase 3 studies of migalastat HCl for FD are
ongoing.
This study describes the first use in patients of an oral
small molecule pharmacological chaperone, rather than
using enzyme replacement therapy, to treat a lysosomal
storage disorder. It shows for the first time in medicine
that such a drug increases the activity, or effectively res-
cues the mutated and dysfunctional enzyme that patients
with Fabry disease have expressed their entire lives. In
addition to being a novel approach for the treatment of
Fabry disease, stabilization of target proteins using small
cell-permeable pharmacological chaperones, may repre-
sent a generally applicable rescue strategy for other dis-
eases that result from improper protein folding and
inefficient cellular targeting [25-27].
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